Research Article
Action Mechanisms of Metformin Combined with Exenatide and Metformin Only in the Treatment of PCOS in Obese Patients
Table 1
Clinical characteristics and biochemical data between the COM and MF group.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BMI, body mass index; WHR, waist-hip ratio; FBG, fasting blood glucose; TT, total testosterone; DHAS, dehydroepiandrosterone sulfate; OGTT, oral glucose tolerance test; HbA1c, hemoglobin A1C; Fins, fasting serum insulin; OGTT-2h INS, 2-hour insulin in OGTT. HOMA-IR, homeostasis model assessment-insulin resistant; TC, total Cholesterol; TG, triglycerides; HDL-c: high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; ApoA1, lipoprotein A1; ApoB, lipoprotein B; LP(a), lipoprotein-a; FFA, free fatty acid; hsCRP, high-sensitivity C-reactive protein; DC, white blood cell count; ALT, alanine aminotransferase; Cr, creatinine. Homeostasis model assessment-Insulin resistant (HOMA-IR) = fasting serum insulin (mIU/L) × fasting blood glucose (FBG, mmol/L)/22.5 [11]. Significant difference between the COM group and MF group (, ). #Significant increase or decrease after treatment in the COM group or MF group (#, ##). |